• Recruiting

NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Multiple Myeloma

NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)


P-BCMA-ALLO1


NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)


Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).


Sponsor

Poseida Therapeutics, Inc

 

ClinicalTrials.gov Identifier: NCT04960579

Official Title: Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)

First Posted : July 14, 2021


Click here for details on Clinicaltrials.gov

 

Drug: Rimiducid


Allogeneic Anti-BCMA CAR T Cells P-BCMA-ALLO1


Allogeneic Anti-BCMA CAR T Cells P-BCMA-ALLO1 (Code C181747)

Allogeneic Anti-BCMA CAR T Cells P-BCMA-ALLO1

Allogeneic Anti-BCMA-CAR-expressing Tscm P-BCMA-ALLO1

Allogeneic Tscm-rich Anti-BCMA CAR T Cells P-BCMA-ALLO1

P-BCMA-ALLO 1

P-BCMA-ALLO-1

P-BCMA-ALLO1

 

Biological: P-BCMA-ALLO1 CAR-T cells

Drug: Rimiducid

 

3858 Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System

Program: Oral and Poster Abstracts

Session: 704. Cellular Immunotherapies: Clinical: Poster III

Hematology Disease Topics & Pathways:

Biological therapies, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Therapies

Monday, December 13, 2021, 6:00 PM-8:00 PM

Click here for details

 

Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting

SAN DIEGO, Dec. 13, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today reported interim results from its Phase 1/2 PRIME clinical trial of P-BCMA-101 for the treatment of relapsed/refractory multiple myeloma (R/R MM) at the 2021 American Society of Hematology (ASH) Annual Meeting.


Click here for details

 

Locations

United States, California

United States, Illinois

United States, Maryland

United States, Oklahoma

United States, Texas




Posts Archive